Medallion Wealth Advisors’s Iterum Therapeutics ITRM Stock Holding History

Medallion Wealth Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,680	Closed	-$50	–	1264
2026 Q1	$50	Hold	1,680	–	–	﹤0.01%	1112
2025 Q4	$563	Hold	1,680	–	–	﹤0.01%	1071
2025 Q3	$1.13K	Hold	1,680	–	–	﹤0.01%	1026
2025 Q2	$1.67K	Hold	1,680	–	–	﹤0.01%	974
2025 Q1	$2.07K	Hold	1,680	–	–	﹤0.01%	913
2024 Q4	$2.07K	Buy	+1,680	New	+$2.63K	﹤0.01%	852

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Medallion Wealth Advisors's ITRM Position: Q2 2026 in Review

Medallion Wealth Advisors sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 1,680 shares — an estimated $50 sold.

Medallion Wealth Advisors first reported a position in ITRM in Q4 2024 and held it in 6 quarters. The position peaked at $2.07K in Q1 2025. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Medallion Wealth Advisors reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
Medallion Wealth Advisors sold 1,680 Iterum Therapeutics shares in Q2 2026, an estimated $50.
Medallion Wealth Advisors first reported a position in Iterum Therapeutics in Q4 2024 and held it in 6 quarters.
Medallion Wealth Advisors's Iterum Therapeutics position peaked at $2.07K in Q1 2025.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.